NVP-BGT226

Research use only, not for human use.

NVP-BGT226 (BGT226) is a potent, dual PI3K/mTOR inhibitor with a preference for PI3Kα and mTOR.

NVP-BGT226 (BGT226) is a potent, dual PI3K/mTOR inhibitor with a preference for PI3Kα (wild type and mutated) and mTOR ( PI3Kα, PI3Kβ and PI3Kγ, IC50=4, 63 and 38 nM); displays potent antiproliferative activity against various human head and neck cancer cell lines in vitro (IC50=7.4-30.1 nM), downregulates the expression levels of the downstream proteins p-p70S6K and p-4E-BP1 in cells, induces cell-cycle arrest at the G0-G1 phase at 60 nM; BGT226 significantly delays tumor growth in a dose-dependent manner, along with suppressed cytoplasmic expression of p-p70S6K and the presence of autophagosome formation in xenografted animal modes.Solid Tumors Discontinued

BGT226;NVP-BGT 226;BGT-226

PI3K/Akt/mTOR signaling

PI3K

PI3Kα;PI3Kβ;PI3Kγ

Cancer

Solid Tumors

1245537-68-1

650.60

C32H29F3N6O6

>98% (HPLC)

10 mM in DMSO

OC(=O)\C=C/C(O)=O.COC1=CC=C(C=N1)C1=CC=C2N=CC3=C(N(C(=O)N3C)C3=CC=C(N4CCNCC4)C(=C3)C(F)(F)F)C2=C1 |c:11,13,20,41,49,t:9,16,18,22,30,32|

8-(6-methoxypyridin-3-yl)-3-methyl-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one with maleic acid

(-20℃)

With Ice Pack

≥ 2 years